alerting health professionals that methylphenidate (Ritalin, etc) might be carcinogenic

The FDA is alerting health professionals that methylphenidate (Ritalin, etc) might be carcinogenic.

They're requiring new info in the package insert...and having manufacturers send out a letter to prescribers.

This concern is based on toxicology studies which show an increased incidence of liver tumors in some mice...but not in rats.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote